STOCK TITAN

ParkerVision (PRKR) registers 16.8M shares for resale; warrants could raise $3.9M

(Neutral)
(Neutral)
Form Type
424B3

Rhea-AI Filing Summary

ParkerVision, Inc. supplements its existing prospectus to register the resale of 16,809,295 shares of Common Stock by selling stockholders. The prospectus supplement explains that the registered shares consist of convertible-note conversions, private placements, shares issued for services and payables, and up to 5,000,000 and 200,000 shares issuable upon exercise of warrants held by Aspire Capital and Tailwinds, respectively.

The company states it will not receive proceeds from the resale by selling stockholders; however, if the Aspire and Tailwinds warrants are exercised for cash, the company would receive up to an aggregate of $3,900,000, which it expects to use for general working capital and corporate purposes. The supplement incorporates a Form 8-K dated March 13, 2026 describing exchange agreements that resulted in issuance of 3,277,099 shares to cancel convertible notes with aggregate principal of $675,000.

Positive

  • None.

Negative

  • None.

Insights

Registration supplements resale rights; issuer proceeds limited to warrant cash exercises.

The supplement registers 16,809,295 shares for resale by existing selling stockholders, describing constituent sources including note conversions, private placements, service/payable issuances, and two warrant tranches. The filing reiterates that the resale proceeds go to selling holders, not the issuer, except for proceeds from potential cash exercises of warrants.

Key legal anchors: the exchanges noted in the attached Form 8-K relied on Section 3(a)(9) for issuance of 3,277,099 shares in cancellation of $675,000 principal; the prospectus supplement attaches the Form 8-K and an exchange agreement exhibit for the record.

Large resale registration creates potential overhang; cash inflow only via warrant exercises.

The registered aggregate of 16,809,295 shares could create secondary supply pressure if selling holders choose to liquidate. The supplement clarifies that the company itself will only receive cash if the Aspire and Tailwinds warrants are exercised for up to $3,900,000.

Material items to watch in subsequent filings include actual warrant exercises and any disclosures on selling-holder identities or planned distributions; timing and holder decisions determine market impact.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What does ParkerVision's prospectus supplement register?

It registers the resale of 16,809,295 shares of Common Stock by selling stockholders, comprising conversions, private placements, service/payable issuances and warrant issuances.

Will ParkerVision receive proceeds from the registered resale?

No, the company will not receive proceeds from sales by the selling stockholders; proceeds from resale go to those holders, not the issuer.

What recent equity exchange did ParkerVision disclose on the attached Form 8-K?

On March 13, 2026, ParkerVision issued 3,277,099 shares to cancel exchange notes with aggregate principal of $675,000, using the Section 3(a)(9) exemption.

How many shares are issuable upon exercise of the registered warrants?

The supplement lists up to 5,000,000 shares issuable under a five-year Aspire warrant and up to 200,000 shares under a three-year Tailwinds warrant, subject to adjustment.

Filed pursuant to Rule 424(b)(3)

Registration No. 333-237762

 

PROSPECTUS SUPPLEMENT No. 71

(to Prospectus dated April 28, 2020)

 

PARKERVISION, INC.

16,809,295 Shares of Common Stock

 

This Prospectus Supplement relates to the prospectus dated April 28, 2020, as amended and supplemented from time to time (the “Prospectus”), which permits the resale by the selling stockholders listed in the Prospectus of up to 16,809,295 shares of our common stock, par value $0.01 per share (“Common Stock”) consisting of (i) up to 4,961,538 shares of Common Stock issuable upon conversion of, and for the payment of interest from time to time at our option, for a convertible promissory note dated September 13, 2019 which has a fixed conversion price of $0.10 per share and convertible promissory notes dated January 8, 2020 which have a fixed conversion price of $0.13 per share (the “Notes”), (ii) an aggregate of 3,907,331 shares of Common Stock issued pursuant to securities purchase agreements dated January 9, 2020, January 15, 2020, March 5, 2020 and March 19, 2020, (iii) an aggregate of 2,740,426 shares of Common Stock issued as payment for services and repayment of short-term loans and other accounts payable, including interest, (iv) up to 5,000,000 shares of Common Stock issuable upon exercise of a five-year warrant with an exercise price of $0.74 per share, subject to adjustment and issued pursuant to a warrant agreement with Aspire Capital Fund LLC (“Aspire”) and (v) up to 200,000 shares of Common stock issuable upon exercise of a three-year warrant with an exercise price of $1.00 per share, subject to adjustment and issued pursuant to a warrant agreement with Tailwinds Research Group LLC (“Tailwinds”).

 

We will not receive proceeds from the sale of the shares of Common Stock by the selling stockholders. To the extent the Aspire and Tailwinds warrants are exercised for cash, we will receive up to an aggregate of $3,900,000 in gross proceeds. We expect to use proceeds received from the exercise of the Aspire and Tailwinds warrants, if any, for general working capital and corporate purposes.

 

This Prospectus Supplement is being filed to update and supplement the information previously included in the Prospectus with the information contained in our Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on March 13, 2026.  Accordingly, we have attached the 8-K to this prospectus supplement.  You should read this prospectus supplement together with the prospectus, which is to be delivered with this prospectus supplement.

 

Any statement contained in the Prospectus shall be deemed to be modified or superseded to the extent that information in this Prospectus Supplement modifies or supersedes such statement.  Any statement that is modified or superseded shall not be deemed to constitute a part of the Prospectus except as modified or superseded by this Prospectus Supplement.

 

This Prospectus Supplement should be read in conjunction with, and may not be delivered or utilized without, the Prospectus.

 

Our Common Stock is listed on the OTCQB Venture Capital Market under the ticker symbol “PRKR.” 

 

Investing in our securities involves a high degree of risk. See Risk Factors beginning on page 6 of this prospectus for a discussion of information that should be considered in connection with an investment in our securities.

 

Neither the SEC nor any such authority has approved or disapproved these securities or determined whether this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

 

The date of this Prospectus Supplement is March 13, 2026.

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

______________

FORM 8-K

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): March 13, 2026

 

PARKERVISION, INC.

(Exact Name of Registrant as Specified in Charter)

     

Florida

000-22904

59-2971472

(State or Other Jurisdiction of Incorporation)

(Commission File Number)

(IRS Employer Identification No.)

 

   

4446-1A Hendricks Avenue Suite 354, Jacksonville, Florida

32207

(Address of Principal Executive Offices)

(Zip Code)

 

(904) 732-6100

(Registrant’s Telephone Number, Including Area Code)

 

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

   

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

   

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

   

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e 4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class

Trading Symbol

Name of Each Exchange on Which Registered

None

 

 

 

 

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter.

 

Emerging growth company   ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ☐

 

 

 

 

Item 1.01              Entry into a Material Definitive Agreement.

 

On March 13, 2026, ParkerVision, Inc., a Florida corporation (the “Company”) entered into  exchange agreements (each an "Exchange Agreement" and collectively, the "Exchange Agreements") with certain holders (the "Holders") of the Company's outstanding convertible promissory notes (the "Exchange Notes").

 

Pursuant to the Exchange Agreements,  the Holders agreed to exchange the outstanding principal amount of the Exchange Notes held by them, together with accrued and unpaid interest thereon through the closing date of the exchange, for shares of the Company’s common stock, par value $0.01 per share (the “Common Stock”) at an exchange price of $0.21 per share (the “Exchange Price”).

 

The exchanges were effected pursuant to Section 3(a)(9) of the Securities Act of 1933, as amended (the “Securities Act”), which provides an exemption from registration for securities exchanged by the issuer with its existing security holders exclusively where no commission or other remuneration is paid or given directly or indirectly for soliciting such exchange.

 

In connection with the exchanges, the Company issued an aggregate of 3,277,099 shares of Common Stock to the Holders in exchange for the cancellation of Exchange Notes having an aggregate outstanding principal amount of $675,000 and accrued and unpaid interest of approximately $13,200.

 

Upon completion of the exchanges, the Exchange Notes surrendered by the Holders were cancelled and extinguished and are no longer outstanding.

 

The Exchange Agreements contain customary representations and warranties of the parties and provide that the Exchange Shares are being issued pursuant to the exemption from registration provided by Section 3(a)(9) of the Securities Act.  The foregoing description of the Exchange Agreements does not purport to be complete and is qualified in its entirety by reference to the form of Exchange Agreement, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.

 

Item 3.02              Unregistered Sales of Equity Securities.

 

The information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference.

 

On March 13, 2026, the Company issued an aggregate of 3,277,099 shares of its Common Stock to the Holders in exchange for the cancellation of Exchange Notes having an aggregate outstanding principal amount of  $675,000 and accrued and unpaid interest of approximately $13,200.

 

The shares of Common Stock issued in the exchanges (the “Exchange Shares”) were issued in reliance upon the exemption from registration provided by Section 3(a)(9) of the Securities Act. The Exchange Shares were issued solely to existing holders of the Exchange Notes and no commission or other remuneration was paid or given directly or indirectly for soliciting the exchanges.

 

 Item 9.01              Financial Statements and Exhibits.

 

(d) Exhibits:

 

Exhibit

Description

10.1* Form of Exchange Agreement, dated March 13, 2026, between ParkerVision, Inc. and the noteholders party thereto *
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

* Filed herewith

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

     

Dated: March 13, 2026

   
   

PARKERVISION, INC.

     
   

By: /s/ Cynthia French

   

Cynthia French

   

Chief Financial Officer